Polycystic Ovary Syndrome Medical Services in China

Polycystic Ovary Syndrome (PCOS) is a common, heterogeneous endocrine-metabolic disorder affecting individuals of reproductive age, characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—diagnosed using the Rotterdam criteria requiring at least two of these three features. PCOS is not merely a gynecologic condition but a systemic disorder with implications for metabolic health, cardiovascular risk, mental well-being, and long-term fertility. Its pathogenesis remains incompletely understood but involves a complex interplay of genetic susceptibility, neuroendocrine dysregulation (e.g., elevated luteinizing hormone [LH] pulse frequency, altered gonadotropin-releasing hormone [GnRH] secretion), insulin resistance, and adipose tissue dysfunction. Hyperinsulinemia exacerbates ovarian androgen production and impairs follicular development, while chronic low-grade inflammation and gut microbiota alterations are emerging as contributing factors. Epidemiologically, PCOS affects approximately 6–12% of women globally, though prevalence varies by diagnostic criteria and population—studies in China report rates of 5.6–8.7% among reproductive-aged women. Risk factors include family history (strong heritability), obesity (especially central adiposity), sedentary lifestyle, prenatal androgen exposure, and early menarche. Importantly, PCOS is underdiagnosed in many settings due to symptom variability and normalization of menstrual irregularities. Beyond reproductive concerns—such as oligomenorrhea, amenorrhea, infertility, and recurrent pregnancy loss—PCOS significantly impacts quality of life. Patients frequently experience anxiety, depression, body image distress, and reduced sexual satisfaction linked to hirsutism, acne, alopecia, and weight gain. Metabolic comorbidities—including prediabetes (30–40%), type 2 diabetes (up to 10% by age 40), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and obstructive sleep apnea—further diminish functional capacity and increase long-term morbidity. Cardiovascular risk markers (e.g., endothelial dysfunction, elevated C-reactive protein) are often present decades before clinical events. Early diagnosis and multidisciplinary management—integrating reproductive endocrinology, nutrition, behavioral health, and metabolic medicine—are essential to mitigate both immediate symptoms and lifelong health consequences.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder affecting approximately 6–12% of reproductive-aged individuals worldwide. It is characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—though diagnosis requires exclusion of other etiologies such as nonclassical congenital adrenal hyperplasia, hyperprolactinemia, thyroid dysfunction, and Cushing’s syndrome. The precise etiology remains incompletely elucidated; however, current evidence supports a multifactorial pathogenesis involving complex interactions among genetic susceptibility, epigenetic modulation, intrauterine environmental exposures, and postnatal metabolic and lifestyle influences.

Genetic factors play a pivotal role in PCOS predisposition. Genome-wide association studies (GWAS) have identified over 20 robust susceptibility loci, many implicating genes involved in gonadotropin action (e.g., LHCGR, FSHR), insulin signaling (e.g., INSR, IRS1, PPARG), and androgen biosynthesis and metabolism (e.g., DENND1A, THADA, RAB5B). Heritability estimates range from 70% to 80%, with first-degree relatives exhibiting significantly increased risk. Notably, PCOS demonstrates familial clustering not only for reproductive phenotypes but also for associated metabolic traits—including insulin resistance, dyslipidemia, and obesity—suggesting shared polygenic architecture across endocrine and metabolic domains.

Environmental and lifestyle factors critically modulate genetic risk. Prenatal exposure to excess androgens—such as maternal hyperandrogenemia or gestational hyperinsulinemia—may induce fetal ovarian and hypothalamic programming alterations, leading to postnatal neuroendocrine dysregulation and ovarian theca cell hyperresponsiveness. Postnatally, obesity—particularly central adiposity—is the most potent environmental amplifier: adipose tissue inflammation promotes insulin resistance, which in turn stimulates ovarian androgen synthesis via enhanced LH-driven 17α-hydroxylase/17,20-lyase activity and suppresses hepatic sex hormone-binding globulin (SHBG) production, thereby increasing bioavailable testosterone. Sedentary behavior, high-glycemic-index diets, and chronic sleep disruption further exacerbate insulin resistance and sympathetic nervous system activation, contributing to GnRH pulse frequency dysregulation and persistent LH hypersecretion.

Endocrine disruptors constitute an emerging class of environmental risk factors. Exposure to bisphenol A (BPA), phthalates, and certain persistent organic pollutants during critical developmental windows has been associated with altered steroidogenesis, impaired folliculogenesis, and insulin signaling defects in epidemiologic and preclinical models. These compounds may act via nuclear receptor interference (e.g., estrogen receptor β, peroxisome proliferator-activated receptors) or epigenetic mechanisms including DNA methylation changes at imprinted loci regulating metabolic and reproductive gene expression.

Triggers of clinical decompensation often involve acute metabolic stressors: rapid weight gain, initiation of progestin-only contraceptives in susceptible individuals, significant psychosocial stress (elevating cortisol and CRH, which stimulate adrenal androgen output), or infectious/inflammatory events that transiently worsen insulin resistance and amplify ovarian androgen production. Perimenarchal onset is common, but symptom severity frequently escalates during adolescence and early adulthood—coinciding with peak insulin resistance and cumulative adipose expansion.

Additional established risk factors include ethnicity (higher prevalence and severity observed in South Asian, Hispanic, and Indigenous populations, likely reflecting gene–environment interactions), low birth weight followed by accelerated childhood weight gain (‘catch-up growth’), and maternal history of gestational diabetes mellitus—underscoring intergenerational transmission of metabolic dysregulation. Importantly, while obesity is neither necessary nor sufficient for PCOS diagnosis, it markedly increases the likelihood of phenotype expression, progression to metabolic syndrome, and long-term cardiovascular morbidity. Conversely, lean PCOS patients exhibit distinct pathophysiologic features—including more pronounced neuroendocrine GnRH/LH dysregulation and relatively preserved insulin sensitivity—highlighting phenotypic heterogeneity rooted in divergent causal pathways. Comprehensive management thus necessitates individualized assessment of underlying drivers rather than uniform application of diagnostic criteria alone.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder affecting approximately 6–12% of reproductive-aged individuals worldwide. It is characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—fulfilling at least two of the three Rotterdam criteria in the absence of other etiologies. As a core condition managed within Reproductive Medicine, PCOS presents with a spectrum of manifestations that evolve across the lifespan and vary significantly in severity and expression.

Early symptoms often emerge during adolescence, typically within 1–3 years after menarche. These include oligomenorrhea (menstrual cycles >35 days apart or <8 cycles/year) or secondary amenorrhea, persistent acne (particularly inflammatory, truncal, or resistant to conventional therapy), and progressive hirsutism—defined as excessive terminal hair growth in androgen-sensitive areas (e.g., upper lip, chin, chest, lower abdomen, inner thighs). Early-onset acanthosis nigricans—a velvety, hyperpigmented, thickened skin lesion commonly found at the nape of the neck, axillae, or groin—is a cutaneous marker of insulin resistance and frequently precedes overt metabolic dysfunction. Subtle signs such as accelerated linear growth followed by premature epiphyseal closure, clitoromegaly (rare but concerning), or premature pubarche may also be observed, warranting evaluation for non-classical congenital adrenal hyperplasia or other hyperandrogenic disorders.

Typical symptoms in adulthood reflect the triad of ovulatory dysfunction, hyperandrogenism, and ovarian structural changes. Menstrual irregularity remains central: up to 80% of affected individuals experience oligo- or anovulation, leading to infertility, unpredictable bleeding, or prolonged amenorrhea. Clinical hyperandrogenism manifests as hirsutism (Ferriman-Gallwey score ≥4–6 depending on ethnicity), moderate-to-severe acne, and androgenic alopecia (female-pattern hair loss, often involving frontal-temporal recession and midline part widening). Pelvic ultrasound typically reveals enlarged ovaries (>10 cm³ volume) with ≥20 follicles per ovary (2–9 mm in diameter) arranged peripherally ('string-of-pearls' appearance) and increased stromal echogenicity. However, polycystic morphology alone is not diagnostic—it is present in ~20–30% of asymptomatic individuals and must be interpreted contextually.

Accompanying symptoms reflect systemic metabolic and neuroendocrine dysregulation. Weight gain—especially central adiposity—is common, though ~20–30% of individuals with PCOS are lean (lean PCOS), often exhibiting more pronounced insulin resistance relative to BMI. Sleep disturbances, including insomnia and obstructive sleep apnea (OSA), occur at higher prevalence due to hormonal and metabolic influences. Mood disorders affect 30–60%: depression, anxiety, and reduced quality of life are strongly associated with both hormonal fluctuations and psychosocial burden of visible symptoms. Chronic fatigue, low libido, and sexual dysfunction are frequently underreported yet clinically significant. Some report cyclical bloating, pelvic discomfort, or mild chronic pelvic pain—though not pathognomonic, these may relate to ovarian stromal hyperplasia or low-grade inflammation.

Complications arise from long-standing hormonal imbalance and metabolic dysregulation. Reproductively, anovulation causes subfertility; recurrent early pregnancy loss occurs in ~30–50% of pregnancies, linked to hyperinsulinemia, hyperandrogenemia, and endometrial dysfunction. Endometrial hyperplasia and carcinoma risk increase 2–6-fold due to unopposed estrogen exposure from chronic anovulation. Metabolically, up to 70% develop insulin resistance independent of obesity; 10–25% progress to type 2 diabetes mellitus by age 40. Dyslipidemia (elevated triglycerides, LDL-C, apolipoprotein B; reduced HDL-C), non-alcoholic fatty liver disease (NAFLD), and hypertension are prevalent. Cardiovascular disease risk is elevated 2-fold, with endothelial dysfunction evident even in adolescents. Psychiatric morbidity includes higher rates of eating disorders, body image distress, and suicidal ideation. Rarely, severe hyperandrogenism may signal late-onset congenital adrenal hyperplasia or androgen-secreting tumors.

Diagnosis relies on comprehensive clinical assessment, biochemical testing, and imaging—not isolated biomarkers. History focuses on menstrual pattern onset, cycle regularity, fertility history, dermatologic symptoms, weight trajectory, and family history of diabetes or cardiovascular disease. Physical examination assesses BMI, waist circumference, blood pressure, hirsutism (Ferriman-Gallwey scoring), acne severity, acanthosis nigricans, and signs of virilization (clitoromegaly, deepening voice, temporal balding). First-line labs include serum testosterone (total and free), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), prolactin, thyroid-stimulating hormone (TSH), and fasting glucose and insulin (HOMA-IR calculation). Pelvic transvaginal ultrasound (TVUS) is recommended for ovarian morphology assessment when clinically indicated, particularly if biochemical hyperandrogenism is absent or ambiguous. Anti-Müllerian hormone (AMH) levels >4.7 ng/mL support diagnosis but are not diagnostic alone. Oral glucose tolerance test (OGTT) is advised for all individuals with PCOS regardless of BMI to detect prediabetes or diabetes.

Differential diagnosis is essential to exclude mimics. Non-classical congenital adrenal hyperplasia (NCCAH) presents similarly but shows markedly elevated 17-hydroxyprogesterone (>10 ng/mL post-ACTH stimulation) and may lack ovarian cysts. Hyperprolactinemia causes anovulation and amenorrhea but lacks hyperandrogenic features; prolactin >25 ng/mL warrants MRI pituitary evaluation. Thyroid dysfunction (especially hypothyroidism) induces menstrual disturbance and can exacerbate weight gain/hair loss—TSH and free T4 clarify this. Premature ovarian insufficiency (POI) features elevated FSH (>25 IU/L) and low estradiol, contrasting with normal/elevated AMH and FSH in PCOS. Androgen-secreting tumors (e.g., ovarian Sertoli-Leydig, adrenal carcinoma) cause rapid-onset virilization, markedly elevated testosterone (>150 ng/dL) or DHEAS (>700 µg/dL), and require urgent imaging (pelvic MRI/abdominal CT). Cushing syndrome exhibits central obesity, striae, hypertension, and abnormal dexamethasone suppression test results. Finally, functional hypothalamic amenorrhea—often related to stress, low energy availability, or excessive exercise—shows low-normal gonadotropins and estradiol, distinguishing it from PCOS’s normo- or hypergonadotropic profile. Accurate differentiation ensures appropriate management: while PCOS requires lifestyle intervention, ovulation induction, and metabolic surveillance, NCCAH needs glucocorticoid replacement, and tumors demand surgical oncology referral.

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder affecting approximately 6–12% of reproductive-aged women globally. Characterized by chronic anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound—diagnosed using the Rotterdam criteria—PCOS is associated with insulin resistance, obesity, dyslipidemia, increased cardiovascular risk, and infertility. Management in the Department of Reproductive Medicine emphasizes individualized, multidisciplinary care targeting both reproductive and metabolic outcomes.

Conservative treatment forms the cornerstone of PCOS management, particularly for overweight or obese patients (BMI ≥25 kg/m²). Lifestyle modification—including structured dietary intervention, regular physical activity, and behavioral support—is evidence-based first-line therapy. A hypocaloric, low-glycemic-index diet combined with ≥150 minutes per week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) improves insulin sensitivity, reduces androgen levels, restores ovulatory function, and enhances fertility outcomes. Weight loss of just 5–10% significantly increases spontaneous ovulation rates by 30–50% and improves menstrual regularity. Cognitive-behavioral therapy (CBT) and digital health platforms are increasingly integrated to support long-term adherence, especially in adolescents and young adults. Sleep hygiene optimization and stress reduction techniques (e.g., mindfulness-based stress reduction) are also recommended given the bidirectional relationship between hypothalamic-pituitary-adrenal axis dysregulation and PCOS pathophysiology.

Pharmacologic interventions are tailored to patient priorities: menstrual regulation, hirsutism/acne control, metabolic improvement, or fertility induction. For menstrual cyclicity and endometrial protection, combined oral contraceptives (COCs) containing ethinyl estradiol and a low-androgenic progestin (e.g., drospirenone, norgestimate) are first-line; they suppress LH-driven ovarian androgen production and reduce endometrial hyperplasia risk. Anti-androgens such as spironolactone (50–100 mg/day) are adjunctive for persistent hirsutism or acne but require concurrent contraception due to teratogenicity. Metformin (500–2000 mg/day) remains indicated for insulin-resistant PCOS, particularly in prediabetic or glucose-intolerant patients, improving ovulation frequency and reducing miscarriage risk. Inovulatory infertility, letrozole (2.5–7.5 mg/day on days 3–7 of the cycle) is now preferred over clomiphene citrate as first-line ovulation induction due to superior live birth rates (RR 1.46) and lower multiple pregnancy risk. Gonadotropins (e.g., recombinant FSH) are reserved for letrozole-resistant cases but require close monitoring to prevent ovarian hyperstimulation syndrome (OHSS). For patients with severe insulin resistance or BMI >35 kg/m² unresponsive to lifestyle and metformin, GLP-1 receptor agonists (e.g., semaglutide) are emerging as adjunctive agents—though not yet FDA-approved for PCOS—demonstrating significant weight loss, improved HOMA-IR, and restored ovulation in early-phase trials.

Surgical treatment is rarely indicated in contemporary practice but retains a niche role. Laparoscopic ovarian drilling (LOD) involves diathermy or laser ablation of 4–10 ovarian stromal sites under general anesthesia. It reduces intraovarian androgen production and improves gonadotropin pulsatility, restoring spontaneous ovulation in ~50–70% of clomiphene-resistant patients within 6 months. LOD avoids the risks of pharmacologic ovulation induction (e.g., OHSS, multiple gestation) and offers durable benefit in selected cases—particularly lean, non-insulin-resistant women with isolated anovulation. However, it carries procedural risks (bleeding, adhesion formation, potential ovarian reserve decline) and is contraindicated in patients with diminished ovarian reserve or prior pelvic surgery. Transvaginal hydrolaparoscopy—a minimally invasive alternative—has shown promise in early studies but lacks robust comparative data.

Treatment advantages in China reflect systemic integration, technological innovation, and population-specific strategies. First, China’s national PCOS screening and management guidelines (2022, Chinese Medical Association) emphasize standardized diagnostic algorithms incorporating AMH measurement and oral glucose tolerance testing (OGTT), enhancing early detection. Second, tiered healthcare delivery enables seamless referral from community clinics to tertiary reproductive centers equipped with real-time ultrasound elastography, automated follicular tracking software, and AI-powered metabolic risk prediction models. Third, traditional Chinese medicine (TCM) is systematically integrated—not as alternative but as complementary therapy—with randomized controlled trials supporting acupuncture plus lifestyle intervention for improved ovulation rates and reduced insulin resistance. Fourth, cost-effectiveness is prioritized: generic metformin and letrozole are widely subsidized, and public insurance covers up to three cycles of ovulation induction and basic IVF for eligible couples. Finally, large-scale cohort registries (e.g., the China PCOS Registry Network) facilitate rapid translation of research into clinical protocols, including precision dosing algorithms for gonadotropins based on AFC and AMH.

Recovery and long-term follow-up are integral to sustainable outcomes. Patients should undergo annual assessment of fasting glucose, lipid profile, blood pressure, and BMI; transvaginal ultrasound every 2–3 years if oligomenorrheic; and mental health screening (PHQ-9, GAD-7) given the high prevalence of depression and anxiety. Postpartum, women with PCOS require intensified metabolic surveillance—especially after gestational diabetes—as lifetime type 2 diabetes risk exceeds 50%. Breastfeeding is strongly encouraged for its insulin-sensitizing effects. For those pursuing fertility, preconception counseling includes optimizing glycemic control, discontinuing spironolactone ≥1 month prior to conception, and initiating folic acid (0.8 mg/day). Longitudinal reproductive counseling addresses perimenopausal transition, as PCOS confers earlier onset of menopause-related symptoms and higher risk of endometrial carcinoma—warranting lifelong gynecologic surveillance. Ultimately, successful PCOS management hinges not on symptom suppression but on empowering patients through education, shared decision-making, and continuity of care across reproductive lifespan.